Efficacy and Influence on Quality of Life of Enalapril as a First Step Treatment of Hypertension

Abstract

205 patients with mild to moderate uncomplicated hypertension participated in a six-month double-blind parallel study performed in a unique center. After a two-week single-blind placebo period, the patients were randomly allocated to receive either Enalapril 20 mg once-a-day or placebo as the first step treatment. They were then followed-up every two weeks and successive doses of hydrochlorothiazide, oxprenolol, and dihydralazine were added until the diastolic pressure was lower than 90 mmHg. After six months, the systolic and diastolic blood pressures were lower in the Enalapril than in the control group (129/82+12/6 mmHg versus 136/86 ± 10/5 mmHg; p < 0.001). Drug withdrawal was necessary for 8 patients in the Enalapril group and for 16 patients in the control group (p < 0.05). The number of daily tablets was 2.7+1.8 in the Enalapril group and 4.4±2.4 in the control group (p < 0.01). Therefore, a stepped-care program based on Enalapril appears significantly more effective than a stepped-care program based on a diuretic.

Key Words:

• Enalapril
• Angiotensin Converting Enzyme Inhibition
• Quality of life
• Six-month Double Blind Trial